Demant A/S: Investor news - Demant obtains regulatory approval for the acquisition of KIND
19 november, 12:40
19 november, 12:40
19.11.2025 12:40:19 CET | Demant A/S | Investor News
Investor news | 19 November 2025 |
Demant obtains regulatory approval for the acquisition of KIND
In June 2025, Demant announced an agreement to acquire KIND Group (KIND), one of the world’s leading retailers of hearing aids with around 650 hearing care clinics. As of today, all regulatory conditions have been fulfilled, which include approvals by both the Austrian and German competition authorities.
With the regulatory conditions now in place, the customary closing conditions remain outstanding, before the parties can close the transaction. This is expected to take place at the beginning of December 2025, at which time we will communicate the financial implications of consolidating KIND into Demant.
Other contacts: René Schneider, CFO Peter Pudselykke, Head of Investor Relations Gustav Høegh, Investor Relations Officer Henrik Axel Lynge Buchter, Manager of External Communications |
Demant is a world-leading hearing healthcare group that offers innovative technologies, solutions and expertise to help people hear better. In every aspect, from hearing care and hearing aids to diagnostic equipment and services, Demant is active and engaged. Headquartered in Denmark, the Group employs more than 22,000 people globally and is present with solutions in 130 countries creating life-changing differences through hearing health. William Demant Foundation holds the majority of shares in Demant A/S, which is listed on Nasdaq Copenhagen and among the 25 most traded stocks.
19 november, 12:40
19.11.2025 12:40:19 CET | Demant A/S | Investor News
Investor news | 19 November 2025 |
Demant obtains regulatory approval for the acquisition of KIND
In June 2025, Demant announced an agreement to acquire KIND Group (KIND), one of the world’s leading retailers of hearing aids with around 650 hearing care clinics. As of today, all regulatory conditions have been fulfilled, which include approvals by both the Austrian and German competition authorities.
With the regulatory conditions now in place, the customary closing conditions remain outstanding, before the parties can close the transaction. This is expected to take place at the beginning of December 2025, at which time we will communicate the financial implications of consolidating KIND into Demant.
Other contacts: René Schneider, CFO Peter Pudselykke, Head of Investor Relations Gustav Høegh, Investor Relations Officer Henrik Axel Lynge Buchter, Manager of External Communications |
Demant is a world-leading hearing healthcare group that offers innovative technologies, solutions and expertise to help people hear better. In every aspect, from hearing care and hearing aids to diagnostic equipment and services, Demant is active and engaged. Headquartered in Denmark, the Group employs more than 22,000 people globally and is present with solutions in 130 countries creating life-changing differences through hearing health. William Demant Foundation holds the majority of shares in Demant A/S, which is listed on Nasdaq Copenhagen and among the 25 most traded stocks.

Analys
Saab kammar hem miljardordrar

Guldrallyt
Fonder

Bolån



Analys
Saab kammar hem miljardordrar

Guldrallyt
Fonder

Bolån


1 DAG %
Senast
OMX Stockholm 30
1 DAG %
Senast
2 849,09
Bostadspriser
27 december, 07:00
Experterna om 2026: Så mycket stiger bostadspriserna
sparande
27 december, 07:00
Shoka Åhrman: 2026 blir ett år för medvetna sparare
Styrränta
26 december, 07:00
Storbankernas prognoser: Så gör Riksbanken 2026
Qualisys
26 december, 07:00
Qualisys är en aktie för dig som gillar småbolag
SBB Norden D
25 december, 07:00
Reportagen från 2025 du inte får missa